Drug Profile
Rivoceranib - HLB
Alternative Names: Aitan; Apatinib; Apatinib mesylate; Apatinib Mesylate Tablets; YN-968-D1Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Advenchen Laboratories LLC
- Developer Elevar Therapeutics; Henan Cancer Hospital; HLB LifeScience; Hunan Cancer Hospital; Jiangsu Hengrui Medicine Co.; Peking University
- Class Amides; Antineoplastics; Cyclopentanes; Nitriles; Pyridines; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastric cancer; Liver cancer
- Phase III Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
- Phase II Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Osteosarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uterine cancer
- Phase I Oesophageal cancer
Most Recent Events
- 18 Jan 2024 Adverse events data from a phase III CARES 310 trial in Liver cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 20 Oct 2023 Efficacy and adverse event data from a phase I/II trial in Colorectal cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 21 Sep 2023 Elevar Therapeutics plans to launch rivoceranib in USA